Swiss pharmaceutical giant Novartis says it has received regulatory approval in Germany for a new swine flu vaccine made using cell cultures instead of egg-based methods.
Novartis, which is based in Basel, described the approval as a "milestone" and said it was pursuing registration of the vaccine, marketed under the name Celtura, in other countries, including Japan and Switzerland.
With demand high because of the pandemic, companies are trying to find a more efficient way of producing swine flu vaccine than the slow method of cultivating seed virus in chicken eggs.
The cell-based technology has previously been licensed in Europe for the production of the seasonal flu vaccine, Novartis said.
"Our modern cell culture technology can enable a faster start-up of vaccine manufacturing, offering the ability to respond more quickly to future pandemic threats," said Andrin Oswald, chief executive of Novartis' Vaccines and Diagnostics division, in a statement on Thursday.
Celtura is currently only produced in Marburg, Germany.
The United States government has awarded Novartis a $487 million (SFr495.7 million) contract to build a second production site in North Carolina, which is expected to be up and running by 2011 or 2012.
swissinfo.ch and agencies